Results 221 to 230 of about 3,018,484 (379)

Drug utilization study of off-label drug use in outpatient department of psychiatry: a prospective study at a tertiary care teaching hospital

, 2017
Meeta D. Vadher, Kamlesh Patel, Deepika Vadher, Sujal Parkar, Chintan Raval   +4 more
openalex   +2 more sources

FDA may allow drug and device companies to promote “off-label” uses [PDF]

, 2007
Janice Hopkins Tanne
openalex   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Drug use in off-label dosage regimes [PDF]

Farmacia Hospitalaria, 2015
Roberto Lozano Ortiz
doaj   +1 more source

Achieving Equitable Access to Obstetric Devices Through Innovation, Improvisation and Off-Label Use. [PDF]

BJOG
Hofmeyr GJ, Singata-Madliki M, Ripa SD, Weeks AD.   +3 more
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Expert consensus on the off-label use of drugs for pediatric rare diseases in China (2025 edition). [PDF]

Transl Pediatr
Mo X, Deng H, Yang J, Li J, Ouyang S, Chen F, Cui Y, Gao X, Jiang H, Li X, Liu L, Liu J, Qiu L, Rong X, Wen Z, Wang J, Zeng P, Zhang W, Zhao X, Zhou J, Chen J, Chen P, Chen W, Chen Z, Fang R, Fan X, Jia Y, Li Z, Li X, Li X, Lin Y, Liu M, Mai H, Miao J, Wang X, Wang Y, Wang J, Wei L, Wu J, Yu S, Zeng L, Zhang B, Zhang H, Zheng Z, Chen X, Xia S, Zhou W, Sun J, Li Y, Rare Disease Expert Committee of Guangdong Pharmaceutical Association.   +49 more
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Off-Label Use of the Multifunctional Occluder for Transcatheter Patent Ductus Arteriosus Closure: An International Experience. [PDF]

J Am Heart Assoc
Lwin N, Ovaert C, Malekzadeh-Milani S, Padovani P, Krasemann T, Georgiev S, Werner O, Houeijeh A, Douchin S, Kramer P, Scarduelli L, Bianco L, Grunenwald C, Hascoët S, Jalal Z, Benbrik N, Lefort B, Navarro Castellanos I, Schubert S, Fraisse A, Baruteau AE.   +20 more
europepmc   +1 more source

P311: Clinical responses to off-label use of phenylbutyrate for STXBP1 and SLC6A1

Kristen Barbour, Tommy Stӧdberg, Anna Larsson, Zachary M. Grinspan   +3 more
openalex   +1 more source